ClinicalTrials.gg
TerminatedNCT01549977Updated Dec 20, 2013Results posted

Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina

A Phase 2 interventional study of Febuxostat and Placebo in Angina, sponsored by Takeda. Terminated at 21 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-12-20.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Why this study was terminated
Business Decision (please see below)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies in Angina Pectoris with a site in United States — 13 open to participants now, 17 under way, 2 of them phase 3. Angina Pectoris · United States.

Enrollment
68th of 73
1 · median 124
Started
2012
with 10 others
Phase 2
15 of 113
1 open now
Registered
45th of 113
by date

Among the 113 studies in Angina Pectoris with a site in United States, this one is the 68th largest by enrollment of the 73 interventional ones that give a count, is one of 11 that started in 2012, is one of 15 in phase 2, and was the 45th registered.

Angina Pectoris

454 studies on the registry are indexed under Angina Pectoris; 68 are open to participants now.

Browse Angina Pectoris studies →

Open to participants now

13 of the 113 studies in Angina Pectoris with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Angina Pectoris studies recruiting now, 35 (74%) set no upper age limit and 1 (2%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Angina Pectoris with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo as an add on to stable anti-anginal therapy, on the total exercise time of participants with Chronic Stable Angina.

Read the detailed description

This is a phase 2 multicenter, randomized, placebo-controlled double-blind study. This study is comprised of a single-blind placebo run-in qualifying phase lasting approximately 3 weeks and a double-blind treatment phase lasting 12 weeks. A safety follow-up visit is scheduled for 2 weeks after last dose of study drug.

All participants will undergo 3 visits during a 3 week, run-in phase (Days -21 to Day 1). During the run-in phase, all participants will receive single-blind placebo. Two exercise treadmill tests (ETTs) will be conducted using the modified Bruce Protocol at Day -14 and at Day -7. The results from the Day -7 ETT will be considered as Baseline.

A total of approximately 100 participants will be randomized 1:1 to receive either febuxostat 80 mg once daily (QD) or placebo QD in a double-blind treatment for 12 weeks, and 5 more visits.

All participants will complete the Seattle Angina Questionnaire (SAQ) and Euroqol 5 dimension (EQ-5D) quality-of-life measurements at Day 1, Week 6 and Week 12/Early Termination (ET) Visit. The investigator will also rate the overall severity of the participant's angina at each visit based on the Canadian Cardiovascular Society Grading of Angina (CCSGA).

This 12-week phase 2 proof-of-concept study was designed to assess the effect of febuxostat as an add-on to stable anti-anginal therapy on the total exercise time of participants with chronic stable angina and a serum urate ≥5 mg/dL. At this time, Takeda has decided to terminate the study for business reasons.

03

Conditions studied

  • Angina

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative, signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant has an serum urate (sUA) ≥5.0 mg/dL.
  4. The participant has a history of angina, defined as:

    1. Minimum of 3-month history of stable angina (at least 2 episodes of chest pain or anginal equivalent in the past 30 days); AND
    2. Receiving at least one chronic anti-ischemic medication(s), including beta blockers, calcium channel blockers and long acting nitrates (doses must be stable for at least 30 days prior to Screening [Day -21]); AND
    3. Coronary artery disease, as defined by:

      • ≥50 % stenosis of ≥1 major coronary artery confirmed by angiography; OR
      • Documented prior myocardial infarction (MI) by enzymes/ (ECG) changes; OR
      • Documented myocardial imaging stress test; OR
      • Prior history of coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) greater than 3 months prior to Screening Day -21.
  5. The participant has estimated (eGFR) >30 mL/min by Modification of Diet in Renal Disease (MDRD) at the Screening visit Day -21.
  6. The participant has a normal/controlled blood pressure at Day 1/Randomization, as defined by the mean of three sitting blood pressures not exceeding 140/90.
  7. The participant is male or female and aged 18 to 85 years, inclusive.
  8. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study.
  9. Participant is on stable (30 days) medication doses prescribed for any underlying medical condition (ie; hypertension, angina) and will remain on stable doses throughout the study duration.
  10. Participant is able to take, in an ongoing manner, nitroglycerine for anginal symptoms.
  11. Symptom-limited exercise duration, during ETT at Day -14 and Day -7, on the modified Bruce Protocol.
  12. Exercise duration for the two ETTs at Day -14 and Day -7 did not differ by more than 20% of the longer of the two times, and did not differ by more than 60 seconds. To be confirmed by the Core ECG Lab prior to the subject being randomized.
  13. Definite ECG signs of ischemia during the ETT at both Day -14 and Day -7 (i.e., 1 additional mm of horizontal or down-sloping ST-segment depression beyond baseline and ≥1 mm below the isoelectric line) are present in at least one standard ECG lead during ETT. The Day -7 ≥1 mm ST-segment depression must be verified by the Core ECG Lab prior to participant being randomized.

Exclusion criteria

Exclusion Criteria:

  1. The participant has received any compound within 30 days prior to Screening Day -21.
  2. The participant has received allopurinol or febuxostat in a previous clinical study or as a therapeutic agent.
  3. The participant has gout or secondary hyperuricemia (e.g., due to myeloproliferative disorder, or organ transplant) or has experienced a gout flare.
  4. The participant has a history of xanthinuria.
  5. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  6. The participant has a history of or allergies to febuxostat or nitroglycerine.
  7. The participant has \<10 g/L at Screening Day -21.
  8. The participant has a systolic blood pressure of less than 100 mmHg.
  9. The participant has a blood pressure of greater than 200/100 at any Screening or Run-in visit.
  10. The participant has a history or clinical manifestations of a significant medical condition that might affect his/her ability to complete the study.
  11. The participant has any of the following at any Screening or Run-in visit:

    1. Resting ST-segment depression ≥1 mm in any lead.
    2. Left bundle-branch block.
    3. Class III or IV heart failure.
    4. Acute coronary syndrome or a coronary revascularization procedure within 3 months of Screening.
    5. Wolff-Parkinson-White syndrome.
    6. Pacemaker or implantable cardioverter defibrillator.
    7. Arrhythmias (i.e., SVT, atrial fibrillation/flutter, VT, or rate related bundle branch blocks).
    8. Left ventricular hypertrophy with repolarization abnormalities.
  12. The participant has a recent history (within the last 3 months) of myocardial infarction, heart failure, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  13. The participant has a for using nitrates (severe anemia, increased intracranial pressure, and those with a known sensitivity or hypersensitivity to nitroglycerin or its ingredients, or other nitrates or nitrites; concomitant use either regularly and/or intermittently, with phosphodiesterase type 5 (PDE5) inhibitors).
  14. The participant has unstable angina that:

    1. Occurs when the participant is at rest.
    2. Is prolonged, usually greater than 20 minutes.
    3. Occurs with increasing in intensity, duration, and/or frequency.
    4. Responds poorly to nitroglycerin (i.e., does not go away after three doses of nitroglycerin or returns after the nitroglycerin helped at first).
  15. The participant is unable to exercise sufficiently to complete ETT due to leg claudication, arthritis, deconditioning, or associated pulmonary disease.
  16. The participant has severe or critical valvular disease documented by echocardiogram, or congenital heart disease.
  17. The participant has (LVEF) less than 35%, as documented by echocardiogram or angiography.
  18. The participant has cardiac conduction defects (i.e., second- or third-degree atrioventricular block, sick sinus syndrome or a >500 msec) at Day -21.
  19. The participant has active acute myocarditis/pericarditis within the 3 months prior to Screening Day -21.
  20. The participant has hypertrophic cardiomyopathy.
  21. The participant has an (ALT) or aspartate aminotransferase (AST) level of greater than 2.0 times the , has active liver disease, or jaundice.
  22. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the Screening Visit.
  23. The participant is required or expected to require excluded medications digoxin and digoxin-containing compounds.
  24. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  25. The participant has participated in another clinical study within the past 30 days.
  26. The participant has a history of extracorporeal external counterpulsation treatment for chronic stable angina within 3 months prior to screening visit.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Febuxostat 80 mg

    Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.

    Drug: Febuxostat

  • Placebo comparator
    Placebo

    Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.

    Drug: Placebo

Interventions

  • Febuxostat tablets

    Also known as: TMX-67, Uloric

  • DrugPlacebo

    Febuxostat placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Exercise Treadmill Testing (ETT) Duration at Week 12

    The change between the duration of ETT at Week 12 relative to Baseline. ETTs were conducted using the modified Bruce Protocol. Participants exercised on a treadmill, starting at 1.7 mph and 0% incline. The intensity of exercise (speed and/or incline) was increased at 3 minute intervals.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Time to Onset of Angina During ETT at Week 12

    The change between the time to onset of angina during the exercise treadmill test (ETT) at Week 12 relative to Baseline.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Time to Onset of ≥1 mm ST-segment Depression During ETT at Week 12

    The change between the time to onset of ≥1 mm ST-segment depression during exercise treadmill test (ETT) at Week 12 relative to Baseline. ST-segment is measured by electrocardiography (ECG) and represents the interval between ventricular depolarization and repolarization.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Maximum ST-segment Depression During ETT at Week 12

    The change between the maximum ST-segment depression during ETT at Week 12 relative to Baseline. ST-segment is measured by electrocardiography (ECG) and represents the interval between ventricular depolarization and repolarization.

    Time frame: Baseline and Week 12

  4. Percentage of Participants Stopping ETT Due to Angina at Week 12

    The percentage of participants who had to stop exercise treatment testing (ETT) due to experiencing angina symptoms at Week 12.

    Time frame: Week 12

07

Results

Posted Dec 20, 2013

Participant flow

Participant flow — Overall Study
MilestoneFebuxostat 80 mgPlacebo
Started10
Completed10
Not completed00

Outcome measures

PrimaryChange From Baseline in Exercise Treadmill Testing (ETT) Duration at Week 12

The change between the duration of ETT at Week 12 relative to Baseline. ETTs were conducted using the modified Bruce Protocol. Participants exercised on a treadmill, starting at 1.7 mph and 0% incline. The intensity of exercise (speed and/or incline) was increased at 3 minute intervals.

Time frame:
Baseline and Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in Time to Onset of Angina During ETT at Week 12

The change between the time to onset of angina during the exercise treadmill test (ETT) at Week 12 relative to Baseline.

Time frame:
Baseline and Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in Time to Onset of ≥1 mm ST-segment Depression During ETT at Week 12

The change between the time to onset of ≥1 mm ST-segment depression during exercise treadmill test (ETT) at Week 12 relative to Baseline. ST-segment is measured by electrocardiography (ECG) and represents the interval between ventricular depolarization and repolarization.

Time frame:
Baseline and Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in Maximum ST-segment Depression During ETT at Week 12

The change between the maximum ST-segment depression during ETT at Week 12 relative to Baseline. ST-segment is measured by electrocardiography (ECG) and represents the interval between ventricular depolarization and repolarization.

Time frame:
Baseline and Week 12

No measurements were reported for this outcome.

SecondaryPercentage of Participants Stopping ETT Due to Angina at Week 12

The percentage of participants who had to stop exercise treatment testing (ETT) due to experiencing angina symptoms at Week 12.

Time frame:
Week 12

No measurements were reported for this outcome.

Adverse events

Collected over 14 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 80 mg—0/1 (0%)1/1 (100%)
Placebo———
Most frequent other events
Most frequent other events
EventFebuxostat 80 mgPlacebo
Blood creatinine increasedInvestigations1/1—
Urinary sediment presentInvestigations1/1—

Baseline characteristics

Age, Customized
Age, Customized(participants)Febuxostat 80 mgPlaceboTotal
18 to 65 years0—0
≥ 65 years1—1
Gender
Gender(participants)Febuxostat 80 mgPlaceboTotal
Female0—0
Male1—1
08

Study locations

21 sites
  • Carmichael, California, United States
  • Fresno, California, United States
  • Irvine, California, United States
  • Paramount, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Tampa, Florida, United States
  • Dunwoody, Georgia, United States
  • Suwanee, Georgia, United States
  • Lexington, Kentucky, United States
  • St. Louis, Missouri, United States
  • St. Peters, Missouri, United States
  • Salisbury, North Carolina, United States
  • Columbus, Ohio, United States
  • Lyndhurst, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Tipton, Pennsylvania, United States
  • San Antonio, Texas, United States
  • Manassas, Virginia, United States
  • Port Orchard, Washington, United States
  • Madison, Wisconsin, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2012
First posted
Mar 9, 2012
Start
Jul 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Dec 20, 2013
Last update
Dec 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01549977
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 9, 2012
Start date
Jul 2012
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Dec 20, 2013
Last update
Dec 20, 2013

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion